| Literature DB >> 26207370 |
Agnès Callol1, Felipe E Reyes-López2, Francisco J Roig3, Giles Goetz4, Frederick W Goetz4, Carmen Amaro3, Simon A MacKenzie5.
Abstract
Infectious diseases are one of the principal bottlenecks for the European eel recovery. The aim of this study was to develop a new molecular tool to be used in host-pathogen interaction experiments in the eel. To this end, we first stimulated adult eels with different pathogen-associated molecular patterns (PAMPs), extracted RNA from the immune-related tissues and sequenced the transcriptome. We obtained more than 2 x 10(6) reads that were assembled and annotated into 45,067 new descriptions with a notable representation of novel transcripts related with pathogen recognition, signal transduction and the immune response. Then, we designed a DNA-microarray that was used to analyze the early immune response against Vibrio vulnificus, a septicemic pathogen that uses the gills as the portal of entry into the blood, as well as the role of the main toxin of this species (RtxA13) on this early interaction. The gill transcriptomic profiles obtained after bath infecting eels with the wild type strain or with a mutant deficient in rtxA13 were analyzed and compared. Results demonstrate that eels react rapidly and locally against the pathogen and that this immune-response is rtxA13-dependent as transcripts related with cell destruction were highly up-regulated only in the gills from eels infected with the wild-type strain. Furthermore, significant differences in the immune response against the wild type and the mutant strain also suggest that host survival after V. vulnificus infection could depend on an efficient local phagocytic activity. Finally, we also found evidence of the presence of an interbranchial lymphoid tissue in European eel gills although further experiments will be necessary to identify such tissue.Entities:
Mesh:
Year: 2015 PMID: 26207370 PMCID: PMC4514713 DOI: 10.1371/journal.pone.0133328
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
454 reads statistics.
Description of different properties of sequenced transcripts, assembly and annotation.
| 454 Statistics | ||
|---|---|---|
|
| ||
|
|
| |
|
|
| |
| max. length | 574 | |
| min. length | 50 | |
| average length (bp) | 257 | |
|
| ||
|
|
| |
| average length (bp) | 576 | |
| average reads per contig | 63 | |
|
|
| |
| max. length | 7838 | |
| min. length | 50 | |
| average length (bp) | 724 | |
|
|
| |
Summary of selected immune-relevant transcripts identified.
| Name | Description | E-value | Best BLAST hit |
|---|---|---|---|
|
| |||
| CR | Complement receptor | 8.00E-26 |
|
| CtlR | C-type lectin receptor | 9.00E-64 |
|
| MR | Mannose receptor C1-like protein | 1.00E-171 |
|
| MR | Mannose-6-phosphate receptor | 7.00E-25 |
|
| NLR | NOD-like receptor | 2.00E-27 |
|
| SR | Scavanger receptor | 2.00E-18 |
|
| TLR1 | Toll-like receptor 1 | 5.00E-18 |
|
| TLR13 | Toll-like receptor 13 | 2.00E-49 |
|
| TLR2 | Toll-like receptor 2 | 1.00E-158 |
|
| TLR3 | Toll-like receptor 3 | 6.00E-46 |
|
| TLR5 | Toll-like receptor 5 | 1.00E-17 |
|
| TLR5s | Toll-like receptor 5 soluble | 4.00E-09 |
|
|
| |||
| CC receptor | C-C chemokine receptor type 4 | 9.00E-54 |
|
| CXC receptor | C-X-C chemokine receptor 4a | 1.00E-139 |
|
| IL-10R | Interleukin-10 receptor | 3.00E-50 |
|
| IL-1R | Interleukin-1 receptor | 2.00E-33 |
|
| IL-2R | Interleukin-2 receptor | 5.00E-22 |
|
| IL-6R | Interleukin-6 receptor | 9.00E-20 |
|
| TNF decoy receptor | TNF decoy receptor | 7.00E-88 |
|
| TNFR | Tumor necrosis factor receptor | 9.00E-171 |
|
|
| |||
| IGγR | Immunoglobulin gamma receptor | 5.00E-10 |
|
| IgεR | Immunoglobulin epsilon receptor | 6.00E-18 |
|
| LYSMD2 | LysM and peptidoglycan-binding domain 2 | 7.00E-60 |
|
| PIR | Polymeric immunoglobulin receptor | 6.00E-10 |
|
| PTX | Pentraxin | 2.00E-45 |
|
| TCRα | T-cell receptor alpha | 2.00E-101 |
|
| TCRβ | T-cell receptor beta | 1.00E-22 |
|
| TCRγ | T-cell receptor gamma | 2.00E-22 |
|
| TfR | Transferrin receptor | 1.00E-41 |
|
|
| |||
| CCL4 | CC chemokine ligand 4 | 2.00E-18 |
|
| CK3 | CC chemokine CK3 | 8.00E-20 |
|
| CXCL13 | CXC chemokine ligand 13 | 3.00E-12 |
|
| IFNα | Interferon alpha | 7.00E-25 |
|
| IFNγ | Interferon gamma | 5.00E-87 |
|
| IL-10 | Interleukin-10 | 7.00E-37 |
|
| IL-11 | Interleukin-11 | 1.00E-30 |
|
| IL-16 | Interleukin-16 | 9.00E-19 |
|
| IL-18 | Interleukin-18 | 2.00E-26 |
|
| IL-1β | Interleukin-1 beta | 5.00E-20 |
|
| IL-8 | Interleukin-8 | 7.00E-32 |
|
| IL-6 | Interleukin-6 | 5.00E-15 |
|
| SCYA112 | CC chemokine SCYA112 | 3.00E-24 |
|
| TNFα-IP2 | Tumor necrosis factor alpha-induced protein 2 | 7.00E-19 |
|
| TNFα-IP8 | Tumor necrosis factor alpha-induced protein 8 | 2.00E-80 |
|
|
| |||
| C3 | Complement component C3 | 3.00E-127 |
|
| C4 | Complement component C4 | 7.00E-178 |
|
| C6 | Complement component C6 | 7.00E-58 |
|
| C9 | Complement component C9 | 1.00E-164 |
|
| CFH | Complement factor H | 2.00E-44 |
|
|
| |||
| A2M-1 | alpha-2-macroglobulin-1 | 6.00E-151 |
|
| Bcl2 | B-cell ligand 2 | 6.00E-25 |
|
| Bcl6 | B-cell ligand 6 | 2.00E-29 |
|
| CD81 | CD81 antigen | 1.00E-84 |
|
| CD83 | CD83 antigen | 2.00E-35 |
|
| HSP70 | Heat shock protein 70 | 0.0 |
|
| HSP90 | Heat shock protein 90 | 0.0 |
|
| IgG | Immunoglobulin gamma light chain | 2.00E-12 |
|
| IgL | Immunoglobulin lambda light chain | 5.00E-31 |
|
| IgM | Immunoglobulin mu heavy chain | 3.00E-46 |
|
| IgT | Immunoglobulin tau heavy chain | 1.00E-05 |
|
| Lyzozyme | Lyzozyme | 5.00E-78 |
|
| MHCI | Major histocompatibility complex class I | 3.00E-76 |
|
| MHCII | Major histocompatibility complex class II | 1.00E-42 |
|
| SART1 | T-cell-recognized antigen | 2.00E-124 |
|
| TCF7 | T-cell transcription factor 7 | 3.00E-65 |
|
| TF | Transferrin | 2.00E-103 |
|
| TF2 | Transferrin 2 | 4.00E-14 |
|
|
| |||
| IRAK4 | Interleukin-1 receptor-associated kinase 4 | 8.00E-22 |
|
| IRF2 | Interferon regulatory factor 2 | 3.00E-50 |
|
| IRF3 | Interferon regulatory factor 3 | 4.00E-41 |
|
| IRF9 | Interferon regulatory factor 9 | 2.00E-17 |
|
| JAK3 | Janus kinase 3 | 8.00E-135 |
|
| JNK | c-Jun N-terminal kinase | 4.00E-80 |
|
| MAPK1 | Mitogen-activator protein kinase | 7.00E-61 |
|
| MAPK2 | Mitogen-activator protein kinase | 1.00E-71 |
|
| MyD88 | Myeloid differentiation primary response gene 88 | 1.00E-14 |
|
| NFκB | Nuclear factor-kappa-B-activating protein | 6.00E-65 |
|
| STAT6 | Signal transducer and activator of transcription 6 | 7.00E-85 |
|
| TOLLIP | Toll-interacting protein | 2.00E-16 |
|
| TRAF3 | TNF receptor-associated factor 3 | 1.00E-27 |
|
Fig 1Principal Component Analysis (PCA) 3-D plot of the gills samples grouped by challenge.
Three principal components are represented, PC1 on X-axis (54.78%), PC2 on Y-axis (14.53%) and PC3 on Z-axis (9.14%).
Fig 2Magnitude of response by mean representation of differential expressed genes (DEGs).
Bars represent the sum of upregulated (in red) and downregulated (in green) DEGs of each sampling group (n = 3). Numbers on the top of each bar represent DEGs number up/downregulated. (A) Loop analysis approach and on (B) Relative analysis against handling control group (HC). Numbers above the columns indicate upregulated/downregulated DEGs.
Fig 3Intensity of response after R99 infection (A-B) or CT285 infection (C-D) represented in number on DEGs grouped in 3 groups by fold change (FC), from 2 to 3, from 3 to 4 and over 4.
Red bars are upregulated transcripts and green bars are downregulated transcripts. (A and C) Loop analysis approach and on (B and D) Relative analysis against handling control group (HC).
Fig 4Detailed representation of most relevant up and downregulated transcripts by mean normalized array expression, corresponding to (A) C-type lectin 1 (clec1), (B) to Myosin regulatory light chain 2 (mrlc2), (C) to Caspase-1 (casp1), (D) to Caspase-3 (casp3), (E) to Interleukin 1 receptor type 2 (il1r2), (F) to TNF receptor-associated factor 3 adaptor (traf3), (G) to Myxovirus resistance (mx), (H) to CXC chemokine receptor type 4 (cxcr4) and (I) to T-cell receptor V alpha (tcrα).
Continuous line represents R99 infection and discontinuous line the CT285 infection. a represents statistical significance (p<0.05) relative to HC; and b statistic significance of p<0.05 by loop analysis.
List of relevant immune-related transcripts regulated during V. vulnificus R99 infection by loop analysis.
Asterisk (*) represents relevant mRNAs with FC<2, however with statistically significant difference (p<0.05).
|
| |||
|
| |||
|
|
|
|
|
|
| Up | 6.45 | - |
|
| Up | 5.37 | Until 12h |
|
| Up | 4.40 | - |
|
| Up | 2.38 | Until 12h |
|
| Down | -2.35 | - |
|
| Down | -2.66 | - |
|
| Down | -2.69 | Until 12h |
|
| Down | -65.69 | Until 03h |
|
| Up | 1.85 (*) | Until 12h |
|
| Down | -1.43 (*) | Until 12h |
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| Down | -2.07 | - |
|
| Down | -2.12 | - |
List of relevant immune-related mRNAs regulated during V. vulnificus CT285 infection by loop analysis.
Asterisk (*) represents relevant mRNAs with FC<2, however with statistically significant difference (p<0.05).
|
| |||
|
| |||
|
|
|
|
|
|
| Up | 3.23 | - |
|
| |||
|
| |||
|
|
|
|
|
|
| Up | 50.88 | - |
|
| Up | 4.34 | - |
|
| |||
|
| |||
|
|
|
|
|
|
| Up | 2.15 | - |
|
| Up | 2.62 | - |
Microarray validation analysis by RT-qPCR absolute quantification based on mRNA fold-change.
| Microarray | RT-qPCR | ||||
|---|---|---|---|---|---|
| Description | Challenge | Fold Change | Regulation | Fold Change | Regulation |
|
| R99 03h | +2.07 | Up | +174.87 | Up |
|
| R99 00h | +4.40 | Up | +10.00 | Up |
|
| R99 00h | -65.69 | Down | -530.69 | Down |
| R99 03h | -39.41 | Down | -26.49 | Down | |
|
| R99 00h | +2.38 | Up | +5.74 | Up |
|
| R99 00h | +5.37 | Up | +3.25 | Up |
|
| CT285 03h | +54.06 | Up | +50.75 | Up |
|
| R99 00h | +6.45 | Up | +7.41 | Up |
|
| R99 00h | +3.48 | Up | +8.07 | Up |